Profile: Celladon Corporation is a biotechnology company that develops molecular therapies for the treatment of heart failure. Our products target the key enzyme deficiency in advanced heart failure. We offer SERCA2a, which regulates calcium cycling and contraction in heart muscle cells. Our Mydicar® product candidate delivers the gene for the SERCA2a enzyme and is currently being tested in phase 1 & 2 clinical trials. We also develop small molecule activators of SERCA2a for acute heart failure.